ライフサイエンスコーパス: serotonin transporter

1 postsynaptic D2 antagonist, and inhibitor of serotonin transporter.

2 ectual disabilities the functionality of the serotonin transporter.

3 rmalin-induced pain, as did mice lacking the serotonin transporter.

4 abolism), serotonin receptor 5-HT4, or mouse serotonin transporter.

5 ts reuptake at dopamine, norepinephrine, and serotonin transporters.

6 ine D2/D3 receptors ([(11)C]raclopride), and serotonin transporter (11)C-N,N-dimethyl-2-(-2-amino-4-c

7 The serotonin transporter 5-HTTLPR genotype has been found t

8 The gene encoding the serotonin transporter (5-HTT) contains a regulatory vari

9 SIDS).Mice with a targeted disruption of the serotonin transporter (5-HTT) develop in the presence of

10 gical signaling in mouse models of disrupted serotonin transporter (5-HTT) function, a risk factor fo

11 A polymorphism in the human serotonin transporter (5-HTT) gene is implicated in susc

12 ic blockade of monoamine oxidase A (MAOA) or serotonin transporter (5-HTT) has antidepressant and anx

13 The serotonin transporter (5-HTT) is a key target for select

14 Because the serotonin transporter (5-HTT) is an important regulator

15 caine self-administration at a high level of serotonin transporter (5-HTT) occupancy with no detectab

16 The serotonin transporter (5-HTT) plays a critical role in r

17 unoreactive (IR) with antibodies against the serotonin transporter (5-HTT) protein were widely distri

18 th are involved in serotonin synthesis), and serotonin transporter (5-HTT) were measured in the ventr

19 imaging with a radiotracer specific for the serotonin transporter (5-HTT), (11)C-McN5652, we found t

20 is associated with reduced expression of the serotonin transporter (5-HTT), particularly in combinati

21 genetic and environmental factors, including serotonin transporter (5-HTTLPR) genotype.

22 variations in the 5-hydroxytryptamine (5-HT; serotonin) transporter (5-HTT) gene are associated with

23 structural variants of the gene encoding the serotonin transporter [5-hydroxytryptamine transporter (

24 corresponding residues (R104E/E493R) in the serotonin transporter also rescues [(3)H](S)-citalopram

25 levels leading to the down-regulation of the serotonin transporter and a variety of 5-HT receptors, i

26 med the causal relationship between amygdala serotonin transporter and an animal's sensitivity to thr

27 MOD-5, the C. elegans orthologue of the serotonin transporter and cellular target of citalopram,

28 ed by platelet serotonin accumulated via the serotonin transporter and could be antagonized using ser

29 be single molecular interactions between the serotonin transporter and MFZ2-12 (a potent cocaine anal

30 functionally important Cl(-) binding site in serotonin transporter and other Cl(-)-dependent transpor

31 tion between microRNA 135 (miR135), and both serotonin transporter and serotonin receptor-1a transcri

32 or binding affinities at DAT, as well as the serotonin transporter and sigma(1) receptors.

33 involved in the pathogenesis of PAH such as serotonin transporter and tenascin-C was elevated in dis

34 18)F]MPPF, two PET radiotracers, marking the serotonin transporter and the 5-HT1AR, respectively.

35 Tyrosines 95 and 175 in the human serotonin transporter and the corresponding phenylalanin

36 ative affinity of the antidepressant for the serotonin transporter and to assess whether concomitant

37 capacitance induced by ligand binding to the serotonin transporter and to the glycine transporters (G

38 May, 2016, were studied with tracers for the serotonin transporter and vesicular monoamine transporte

39 hibits both the dopamine transporter and the serotonin transporter, and simple chemical modifications

40 and interactions with dopamine transporter, serotonin transporter, and vesicular monoamine transport

41 erotonin reuptake inhibitors targeting brain serotonin transporters are first-line treatments for bip

42 croscopy to study the diffusion of the human serotonin transporter at the ER and the plasma membrane.

43 There was no association between raphe serotonin transporter availability and fatigue, depressi

44 sease subgroup had significantly lower raphe serotonin transporter availability but less severe stria

45 Parkinson's disease had significantly lower serotonin transporter availability in the brainstem raph

46 Increased serotonin transporter availability in the patients with

47 on's disease patients and that reduced raphe serotonin transporter availability is associated with th

48 s and release, are downregulated in SAD, and serotonin transporter availability might be increased; h

49 Raphe serotonin transporter availability over the entire Parki

50 In tremulous patients, raphe serotonin transporter availability was also associated w

51 d [11C]DASB binding potential as an index of serotonin transporter availability were acquired during

52 hy, markers of dopamine storage capacity and serotonin transporter availability, to investigate wheth

53 nding in the brainstem raphe nuclei reflects serotonin transporter availability.

54 puted tomography is a marker of dopamine and serotonin transporter availability.

55 Low midbrain serotonin transporter binding appears to be related to t

56 Future studies should investigate midbrain serotonin transporter binding as a predictor of suicidal

57 nt with postmortem work showing low midbrain serotonin transporter binding capacity in depressed suic

58 There was no difference in serotonin transporter binding comparing all depressed su

59 We have also reported low in vivo serotonin transporter binding in major depressive disord

60 Depressed suicide attempters had lower serotonin transporter binding in midbrain compared with

61 ding, VMAT2 binding, (18)F-FDOPA uptake, and serotonin transporter binding in multiple brain regions

62 rgic projections together with extrastriatal serotonin transporter binding in Parkinson disease.

63 ehavior and completed suicide, including low serotonin transporter binding in postmortem studies of c

64 Serotonin transporter binding in the cortex did not diff

65 rkinson's disease had significantly elevated serotonin transporter binding in the hypothalamus (compa

66 manifest Parkinson's disease show increased serotonin transporter binding in the striatum, brainstem

67 We quantified regional brain serotonin transporter binding in vivo in depressed suici

68 sion who attempt suicide have lower midbrain serotonin transporter binding potential compared with th

69 region (F1,10 = 0.83; P = .38), and midbrain serotonin transporter binding potential did not predict

70 Objectives: To determine whether serotonin transporter binding potential in the lower mid

71 el-based analysis localized further relative serotonin transporter binding reductions in the cingulat

72 atients with fatigue had significantly lower serotonin transporter binding than patients without fati

73 onin transporter promoter gene (5-HTTLPR) on serotonin transporter binding using in vivo imaging tech

74 In vivo brain serotonin transporter binding was measured using positro

75 11)C]DASB to quantify in vivo regional brain serotonin transporter binding.

76 Lower serotonin transporter BP(1) in bipolar depression overla

77 s with bipolar disorder had 16% to 26% lower serotonin transporter BP(1) in the midbrain, amygdala, h

78 allelic 5-HTTLPR genotypes were unrelated to serotonin transporter BP(1).

79 e inhibition, excellent selectivity over the serotonin transporter, but no selectivity over the dopam

80 onin transporter occupancy prevented similar serotonin transporter calculations.

81 ng PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutat

82 factor (BDNF), reduced Glut4, with unchanged serotonin transporter concentrations were noted in (F) (

83 y; on the other candidate genes, such as the serotonin transporter, continue to dominate in genetic s

84 s provide evidence that molecular imaging of serotonin transporters could be used to visualise premot

85 ASB PET non-displaceable binding to quantify serotonin transporter density.

86 er was significantly higher than that of the serotonin transporter, despite similar in vitro potencie

87 upport the hypothesis that inhibition of the serotonin transporter during neonatal life by an SSRI is

88 necessary to confirm that inhibition of the serotonin transporter during the neonatal period is suff

89 findings provide evidence that high amygdala serotonin transporter expression contributes to the high

90 Participants with low serotonin transporter expression had higher signal-to-no

91 This indicates that serotonin transporter expression, eventually in combinat

92 havior in any of the targeted brain regions, serotonin transporter expression, specifically within th

93 extent of down-regulation is potentiated by serotonin transporter function (IC50 of 2.3 +/- 1.0 muM,

94 We also developed a robust assay of serotonin transporter function and modulation by drugs.

95 associations between genetic variability in serotonin transporter function and stress-related psycho

96 patients seem to have upregulation of brain serotonin transporter function at the early phase of the

97 us underlying interindividual differences in serotonin transporter function in humans.

98 reuptake inhibitor, fluvoxamine, to inhibit serotonin transporter function in ovariectomized rats.

99 ch locus, supporting the notion of increased serotonin transporter functioning being pathogenetically

100 lymorphisms (5-HTTLPR and STin2 VNTR) of the serotonin transporter gene (5-HTT), we find strong evide

101 46)- which directs reduced expression of the serotonin transporter gene (5-HTT).

102 Polymorphisms in the promoter region of the serotonin transporter gene (5-HTTLPR) and exposure to ea

103 A promoter polymorphism in the serotonin transporter gene (5-HTTLPR) has been reported

104 a polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR) offering equivocal

105 a polymorphism in the promoter region of the serotonin transporter gene (5-HTTLPR), we found that ind

106 ed the hypothesis that a polymorphism in the serotonin transporter gene (locus, SLC6A4; variant, sero

107 etic variation in the promoter region of the serotonin transporter gene (serotonin transporter-linked

108 Polymorphisms of the serotonin transporter gene (SERT) have been associated w

109 udies have reported associations between the serotonin transporter gene (SLC6A4) and alcohol, heroin,

110 hism (5HTTLPR) in the promoter region of the serotonin transporter gene (SLC6A4) and exposure to chil

111 We show that variants at the serotonin transporter gene (SLC6A4) and serotonin 2A rec

112 ects in two candidate genes of interest--the serotonin transporter gene (SLC6A4) and the integrin bet

113 rphisms in the repeat upstream region of the serotonin transporter gene (SLC6A4) are associated with

114 R polymorphism in the promoter region of the serotonin transporter gene (SLC6A4) has been found to mo

115 Genetic variation in the serotonin transporter gene (SLC6A4) is associated with v

116 nalyses of common functional variants of the serotonin transporter gene (SLC6A4), a long-standing OCD

117 rphism located in the promoter region of the serotonin transporter gene (SLC6A4), is implicated in sp

118 he well-studied 5-HTTLPR polymorphism in the serotonin transporter gene (SLC6A4).

119 iry: variation in the promoter region of the serotonin transporter gene (SLC6A4; also known as 5-HTT)

120 e-environment interactions (GxE) between the serotonin transporter gene and stress on risk of depress

121 entifying two common genetic variants of the serotonin transporter gene and their association with in

122 Participants with a variant at the serotonin transporter gene contribute more, leading to g

123 plicated in emotion regulation revealed that serotonin transporter gene expression in the ventrolater

124 The serotonin transporter gene has previously been implicate

125 Additionally, allelic variation in the serotonin transporter gene is associated with prevalence

126 Polymorphisms in the serotonin transporter gene may be a key risk factor as w

127 igates whether a genetic polymorphism of the serotonin transporter gene moderates susceptibility to a

128 e is associated with brain morphology is the serotonin transporter gene polymorphism within the promo

129 rs1042173-TT (SLC6A4-LL/TT) genotypes in the serotonin transporter gene predicted a significant reduc

130 d that increased promoter methylation of the serotonin transporter gene predicted increased threat-re

131 re we show that a common polymorphism in the serotonin transporter gene relates to an accurate and ro

132 R, a functional promoter polymorphism of the serotonin transporter gene SLC6A4, influences cerebral c

133 The HTTLPR, a functional polymorphism of the serotonin transporter gene solute carrier family 6 (neur

134 s, carrying at least one short allele of the serotonin transporter gene was associated with a 26% hig

135 Individuals with 1 or 2 short alleles of the serotonin transporter gene were at higher risk for an in

136 Variation at the serotonin transporter gene, SLC6A4, has been associated

137 methylation of the proximal promoter of the serotonin transporter gene, which predicts greater incre

138 Variation in the serotonin transporter gene-linked polymorphic region (5-

139 ncreased in short-allele (s) carriers of the serotonin transporter gene.

140 ol) carried at least one short allele of the serotonin transporter gene.

141 renaline transporter (NAT) gene, and not the serotonin transporter genes, in dopaminergic cells, whic

142 s meta-analysis yielded no evidence that the serotonin transporter genotype alone or in interaction w

143 structural characterization of dopamine and serotonin transporters have opened the way for structure

144 Human serotonin transporter (hSERT) activity expressed in HeLa

145 tagonists with and without concomitant human serotonin transporter (hSerT) activity.

146 ridinium (MPP(+)) as reporters for the human serotonin transporter (hSERT) in single cells.

147 spite the well-established role of the human serotonin transporter (hSERT) in the treatment of depres

148 Serotonin (5-HT) uptake by the human serotonin transporter (hSERT) is driven by ion gradients

149 The human serotonin transporter (hSERT) is responsible for the ter

150 e photoaffinity ligands (PALs) for the human serotonin transporter (hSERT) were synthesized based on

151 Unlike for the human serotonin transporter (hSERT), in which direct binding o

152 SLC6 family of proteins, including the human serotonin transporter (hSERT), utilize Na(+), Cl(-), and

153 ermined X-ray crystal structure of the human serotonin transporter (hSERT).

154 Future work might establish whether serotonin transporter imaging is suitable as an adjuncti

155 Serotonin transporter immunohistochemistry or cytochrome

156 lain discrepant in vivo findings quantifying serotonin transporter in depression.

157 t in the relative importance of dopamine and serotonin transporters in the abuse-related-effects of c

158 ypoxic or transgenic mice overexpressing the serotonin-transporter in SMCs (SM22-5HTT+ mice).

159 ucing doses of SSRIs reduces their effect on serotonin transporter inhibition in a linear manner.

160 thesized and characterized as norepinephrine/serotonin transporter inhibitors.

161 E2, the density of fibers immunoreactive for serotonin transporter innervating the auditory midbrain

162 Although residues in the human serotonin transporter involved in direct Cl(-) coordinat

163 s in humans mirror the phenotypic effects of serotonin transporter knockout in mice, highlighting the

164 he amygdala and cingulate cortex between the serotonin transporter knockout mouse, a genetic animal m

165 Parkinson's disease; and (ii) whether raphe serotonin transporter levels correlate with severity of

166 rs increased SLC6A4 transcription, increased serotonin transporter levels in brain and other tissues

167 The serotonin transporter ligand (11)C-3-amino-4(2-dimethyla

168 e investigated with SPECT using the dopamine/serotonin transporter ligand (123)I-N-omega-fluoropropyl

169 ied the influence of genetic variance in the serotonin transporter linked polymorphic region (5-HTTLP

170 pothesis: 1) observational studies about the serotonin transporter linked polymorphic region (5-HTTLP

171 ing the report of an interaction between the serotonin transporter linked polymorphic region (5-HTTLP

172 Additionally, we considered serotonin transporter-linked polymorphic region (5-HTTLP

173 Genetic variation at the serotonin transporter-linked polymorphic region (5-HTTLP

174 Here, we postulated that the serotonin transporter-linked polymorphic region (5-HTTLP

175 er region of the serotonin transporter gene (serotonin transporter-linked polymorphic region [5-HTTLP

176 less than 150 nucleotides centromeric of the serotonin transporter-linked polymorphic region indel kn

177 ta suggest that differential function of the serotonin transporter may mediate differential response

178 ed decreases in tryptophan hydroxylase 2 and serotonin transporter mRNA in the dorsal raphe dorsalis

179 Average dopamine and serotonin transporter occupancies increased with increas

180 Mean dopamine and serotonin transporter occupancies were 33% +/- 11% and 2

181 Dopamine and serotonin transporter occupancies were estimated from PE

182 We examined the PET imaging data of serotonin transporter occupancy by SSRIs and found that

183 cupancy was extrapolated (85%); however, low serotonin transporter occupancy prevented similar seroto

184 f SEP-225289 to investigate its dopamine and serotonin transporter occupancy.

185 Knockout of the serotonin transporter or postnatal blockade with selecti

186 and from mice with PH induced by hypoxia or serotonin-transporter overexpression (SM22-5HTT(+) mice)

187 nomethyl-phenylsulfaryl)-benzonitrile (DASB) serotonin transporter PET imaging was performed in a sub

188 onin signaling in the form of a common human serotonin transporter polyadenylation polymorphism (STPP

189 Furthermore, we show that the serotonin transporter polyadenylation profile associated

190 When infant genotype for serotonin transporter polymorphism was taken into accoun

191 and 145 control) was genotyped for a common serotonin transporter polymorphism.

192 association of the STin2 and/or the 5-HTTLPR serotonin transporter polymorphisms in adult males with

193 elationship of a functional variation of the serotonin transporter promoter gene (5-HTTLPR) on seroto

194 Conversely, the serotonin transporter promoter polymorphism (5-HTTLPR) s

195 hypothesis that the S allele of the 5-HTTLPR serotonin transporter promoter region is associated with

196 was no association between genotypes of the serotonin transporter promoter region polymorphism and s

197 of serotonin and serotonergic receptors are serotonin transporter protein (SERT or soluble carrier p

198 of a genetic polymorphism (5-HTTLPR) in the serotonin transporter protein gene on the likelihood tha

199 ions in TnaT-D268S, in wild type TnaT and in serotonin transporter provide direct evidence for the in

200 phenylsulfanyl)- benzonitrile ([11C]DASB), a serotonin transporter radioligand.

201 ing the dopamine transporter (DAT(-/-)), the serotonin transporter (SERT(-/-)), or both (DAT(-/-)SERT

202 of the alternate conformation in a mammalian serotonin transporter (SERT) (a member of the same trans

203 Serotonin transporter (SERT) and 5-HT(2A) receptor avail

204 Expression of 14 5-HT receptor subtypes, the serotonin transporter (SERT) and 5-HT-producing enzymes

205 The serotonin transporter (SERT) and other monoamine transpo

206 ion tomography for two serotonergic markers: serotonin transporter (SERT) and serotonin 1A (5-HT1A) r

207 ial smooth muscle cell proliferation via the serotonin transporter (SERT) and serotonin can induce pu

208 The serotonin transporter (SERT) and the norepinephrine tran

209 y measure the interaction forces between the serotonin transporter (SERT) and the S- and R-enantiomer

210 f juvenile grasshopper mice labeled with the serotonin transporter (SERT) antibody, revealing a strik

211 Inhibitors of the serotonin transporter (SERT) are widely used antidepress

212 We have developed a homology model for the serotonin transporter (SERT) based on the crystal struct

213 ptoms was associated with change in cerebral serotonin transporter (SERT) binding following intervent

214 iencephalon, which may reflect predominantly serotonin transporter (SERT) binding.

215 Antidepressants target the serotonin transporter (SERT) by inhibiting serotonin reu

216 The serotonin transporter (SERT) controls synaptic serotonin

217 ty of using (11)C-DASB for quantification of serotonin transporter (SERT) density and affinity in viv

218 lthio)benzylamine ((11)C-HOMADAM) imaging of serotonin transporter (SERT) density in healthy control

219 Mutations in the C terminus of the serotonin transporter (SERT) disrupt folding and export

220 of intracellular solute-binding to the human serotonin transporter (SERT) expressed in HEK-293 cells.

221 In addition, serotonin transporter (SERT) expression was upregulated

222 panes 1-4 were synthesized as ligands of the serotonin transporter (SERT) for use as positron emissio

223 Export of the serotonin transporter (SERT) from the endoplasmic reticu

224 ould be via HPA axis-dependent impairment of serotonin transporter (SERT) function, the high-affinity

225 obesity, potentially attributed to a reduced serotonin transporter (SERT) function.

226 k and reports on the optimization of DAT and serotonin transporter (SERT) functional assays, as well

227 identified genetic interactions between the serotonin transporter (SERT) gene and ITGB3, which encod

228 The s/l promoter polymorphism in the serotonin transporter (SERT) gene moderates both trait e

229 Antagonist dissociation experiments on the serotonin transporter (SERT) have also unveiled the exis

230 t years, a number of PET studies imaging the serotonin transporter (SERT) have been used and provided

231 opane (betaFEpZIENT, 1) was synthesized as a serotonin transporter (SERT) imaging agent for both posi

232 rivatives 40-42) were prepared and tested as serotonin transporter (SERT) imaging agents.

233 oimaging, and genetic findings implicate the serotonin transporter (SERT) in autism spectrum disorder

234 PET of the serotonin transporter (SERT) in the brain is a useful to

235 The serotonin transporter (SERT) is a major regulator of ser

236 Serotonin transporter (SERT) is a transmembrane transpor

237 The serotonin transporter (SERT) is an integral membrane pro

238 Serotonin transporter (SERT) is only weakly expressed in

239 The serotonin transporter (SERT) is responsible for reuptake

240 Serotonin transporter (SERT) is responsible for reuptake

241 Serotonin transporter (SERT) is responsible for the re-u

242 Serotonin transporter (SERT) is the main target for wide

243 The serotonin transporter (SERT) is the primary target for a

244 The serotonin transporter (SERT) is the principal mechanism

245 Wild type and serotonin transporter (SERT) knockout mice underwent CR

246 ocampal brain slices from wild-type rats and serotonin transporter (SERT) knockout mice.

247 The serotonin transporter (SERT) maintains serotonergic neur

248 rotonin (5-HT) into neurons and other cells, serotonin transporter (SERT) modulates the action of 5-H

249 rported anti-addiction properties, inhibited serotonin transporter (SERT) noncompetitively by decreas

250 opiate withdrawal, has been shown to inhibit serotonin transporter (SERT) noncompetitively, in contra

251 to assess D(2)/D(3), 5-HT(1A), 5-HT(2A) and serotonin transporter (SERT) occupancies of brexpiprazol

252 The serotonin transporter (SERT) on the plasma membrane is t

253 This 5-HT signal was not potentiated by the serotonin transporter (SERT) or the noradrenaline transp

254 The serotonin transporter (SERT) plays a critical role in re

255 Serotonin transporter (SERT) plays a critical role in re

256 Serotonin transporter (SERT) plays a critical role in re

257 Reduced expression of the serotonin transporter (SERT) promotes anxiety and cocain

258 The serotonin transporter (SERT) regulates neurotransmission

259 The serotonin transporter (SERT) regulates neurotransmitter

260 The serotonin transporter (SERT) terminates neurotransmissio

261 The serotonin transporter (SERT) terminates serotonergic neu

262 The serotonin transporter (SERT) terminates serotonergic sig

263 The serotonin transporter (SERT) terminates serotonin signal

264 ability in IBS-D including a decrease in the serotonin transporter (SERT) which is also seen followin

265 zing enzyme tryptophan hydroxylase (TPH) and serotonin transporter (SERT) with semiquantitative immun

266 lore structure-activity relationships at the serotonin transporter (SERT), a series of (+/-)-4- and 5

267 isms regulating disulfide bond formation for serotonin transporter (SERT), an oligomeric glycoprotein

268 f its DAT affinity were only observed at the serotonin transporter (SERT), dopamine D2-like, and sigm

269 how SSRIs, which inhibit the plasma membrane serotonin transporter (SERT), modulate hemostasis.

270 n, (123)I-FP-CIT has modest affinity for the serotonin transporter (SERT), predominantly represented

271 nity for DAT and robust selectivity over the serotonin transporter (SERT), whereas affinity improved

272 rter (LeuT), dopamine transporter (DAT), and serotonin transporter (SERT)-by the use of porcine pepsi

273 Rodents exposed to serotonin transporter (SERT)-inhibiting antidepressants

274 ission is modulated by the membrane-embedded serotonin transporter (SERT).

275 d this approach on the cocaine-sensitive rat serotonin transporter (SERT).

276 he norepinephrine transporter (NET) over the serotonin transporter (SERT).

277 ds with high affinity and selectively to the serotonin transporter (SERT).

278 affinity and selectivity to the human brain serotonin transporter (SERT).

279 istal colon due to an impairment/loss in the serotonin transporter (SERT).

280 llular serotonin (5-HT) by the high-affinity serotonin transporter (SERT).

281 The serotonin transporter (SERT, SLC6A4) in the platelet pla

282 subsequently causes the translocation of the serotonin transporter (SERT, SLC6A4) to the synaptic ter

283 The serotonin transporter (SERT/SLC6A4) has a rich pharmacol

284 the C terminus in supporting folding of the serotonin transporter (SERT; SLC6A4).

285 Using immunostaining for the serotonin transporter, SERT, we describe the complete pa

286 to the lumen and subsequently removed by the serotonin transporter, SERT.

287 s serotonergic [i.e., immunopositive for the serotonin transporter; SERT].

288 RH, the mineralocorticoid receptor (MR), the serotonin transporter (Serta) or GR itself.

289 Channel properties are also attributed to serotonin transporters (SERTs); however, SERT regulation

290 ciation of region-specific expression of the serotonin transporter (SLC6A4) and serotonin receptor (H

291 The serotonin transporter (SLC6A4) has been associated with

292 ential interactions between these factors on serotonin transporter (slc6a4) mRNA expression, we inves

293 ters of the SLC6 family, including the human serotonin transporter (SLC6A4), is critical for efficien

294 onferring susceptibility to ASD are PTEN and Serotonin transporter (SLC6A4).

295 norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission

296 f the maternal polymorphism, 5HTTLPR, in the serotonin transporter, SLC6A4, coupled with prenatal str

297 Antidepressants that block the serotonin transporter, (Slc6a4/SERT), selective serotoni

298 activation of p38alpha MAPK translocated the serotonin transporter to the plasma membrane and increas

299 ubstituents on the 7-position with the human serotonin transporter Tyr175 versus dopamine transporter

300 and intermediate, but not low, affinity for serotonin transporter were associated with upper gastroi